首页/数据集/Bortezomib resistance in Mantle Cell Lymphoma (MCL) is associated with plasmacytic differentiation

Bortezomib resistance in Mantle Cell Lymphoma (MCL) is associated with plasmacytic differentiation

ChEBI2010-10-13 更新2026-07-21 收录

肿瘤耐药机制

套细胞淋巴瘤

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-20915 数据链接链接失效反馈

官方服务：

资源简介：

Bortezomib resistance in Mantle Cell Lymphoma (MCL) is associated with plasmacytic differentiation

应用场景：

创建时间：

2010-10-13

肿瘤耐药机制

miRNA调控

The mammalian target of rapamycin (mTOR) is a central regulator of cell proliferation. Inhibitors of mTOR are being evaluated as anti-tumor agents. Given the emerging role of microRNAs (miRNAs) in tum

NIAID Data Ecosystem70

YAP activation mediates acquired resistance to ALK inhibitor in ALK rearranged non–small cell lung cancer

肿瘤耐药机制

ALK靶向治疗

To investigate a possible candidate for overcoming the acquired resistance to ALK-TKI, we established an in vitro model of acquired resistance to crizotinib (H3122-CR) by exposing EML4-ALK–positive H3

NIAID Data Ecosystem40

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping. Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping

肿瘤耐药机制

表观遗传学分析

In this report, we generated eight matched pairs of vemurafenib sensitive/resistant melanoma lines and subjected these to concurrent RNA-seq and H3K27Ac ChIP-seq analysis. Globally, we identified two

NIAID Data Ecosystem30

Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens

肿瘤耐药机制

转录组药物响应

Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types

NIAID Data Ecosystem50

TABLE 2 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma

套细胞淋巴瘤

机器学习模型

Performance metrics of prognostic MCL models

NIAID Data Ecosystem40